[1] Mederos MA, Reber HA, Girgis MD. Acute pancreatitis: a review[J].JAMA,2021,325(4):382-390.DOI:10.1001/jama.2020.20317.
[2] Lee PJ, Papachristou GI. New insights into acute pancreatitis[J].Nat Rev Gastroenterol Hepatol,2019,16(8):479-496.DOI:10.1038/s41575-019-0158-2.
[3] Hernandez P, Passi N, Modarressi T, et al. Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis[J].Curr Atheroscler Rep,2021,23(11):72.DOI:10.1007/s11883-021-00962-z.
[4] Guo YY, Li HX, Zhang Y, et al. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities[J].Discov Med,2019,27(147):101-109.
[5] Moggia E, Koti R, Belgaumkar AP, et al. Pharmacological interventions for acute pancreatitis[J].Cochrane Database Syst Rev,2017,4(4):CD011384.DOI:10.1002/14651858.CD011384.pub2.
[6] Kathi P, Smith S, Rabadi R, et al. Omeprazole-associated necrotizing pancreatitis[J].Am J Ther,2020,27(4):e411-e412.DOI:10.1097/MJT.0000000000000999.
[7] Al-Omran M, Albalawi ZH, Tashkandi MF, et al. Enteral versus parenteral nutrition for acute pancreatitis[J].Cochrane Database Syst Rev,2010,2010(1):CD002837.DOI:10.1002/14651858.CD002837.pub2.
[8] Song J, Zhong Y, Lu X, et al. Enteral nutrition provided within 48 hours after admission in severe acute pancreatitis: A systematic review and meta-analysis[J].Medicine (Baltimore),2018,97(34):e11871.DOI:10.1097/MD.0000000000011871.
[9] 余婷媛,税金凤,李亚男. 奥美拉唑联合免疫肠内营养治疗重症急性胰腺炎的临床疗效及对T淋巴细胞亚群和细胞因子的影响[J]. 解放军医药杂志,2018,30(3):73-76.DOI:10.3969/j.issn.2095-140X.2018.03.019.
[10] 中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 中国实用外科杂志,2021,41(7):739-746.DOI:10.19538/j.cjps.issn1005-2208.2021.07.03.
[11] Greenberg JA, Hsu J, Bawazeer M, et al. Clinical practice guideline: management of acute pancreatitis[J].Can J Surg,2016,59(2):128-140.DOI:10.1503/cjs.015015.
[12] Zheng Y, Zhou Z, Li H, et al. A multicenter study on etiology of acute pancreatitis in Beijing during 5 years[J].Pancreas,2015,44(3):409-414.DOI:10.1097/MPA.0000000000000273.
[13] Kadiyala V, Suleiman SL, McNabb-Baltar J, et al. The Atlanta classification, revised Atlanta classification, and determinant-based classification of acute pancreatitis: which is best at stratifying outcomes?[J].Pancreas,2016,45(4):510-515.DOI:10.1097/MPA.0000000000000477.
[14] Bukowski JS, Dembiński Ł, Dziekiewicz M, et al. Early enteral nutrition in paediatric acute pancreatitis-a review of published studies[J].Nutrients,2022,14(16):3441.DOI:10.3390/nu14163441.
[15] Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions[J].BMC Med,2016,14(1):172.DOI:10.1186/s12916-016-0724-1.
[16] Wang J, Barbuskaite D, Tozzi M, et al. Proton pump inhibitors inhibit pancreatic secretion: role of gastric and non-gastric H+/K+-ATPases[J].PLoS One,2015,10(5):e0126432.DOI:10.1371/journal.pone.0126432.
[17] Zhang S, Han Z, Zhang Y, et al. Proton pump inhibitors were associated with reduced pseudocysts in acute pancreatitis: a multicenter cohort study[J].Front Pharmacol,2021,12:772975.DOI:10.3389/fphar.2021.772975.
[18] Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression[J].BMC Med,2016,14(1):179.DOI:10.1186/s12916-016-0718-z.
[19] Demcsák A, Soós A, Kincses L, et al. Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis - an international cohort study[J].Pancreatology,2020,20(7):1323-1331.DOI:10.1016/j.pan.2020.08.009.
[20] 夏永欣,刘晓政,张向东,等.奥美拉唑联合生长抑素治疗SAP的临床疗效和安全性[J].世界华人消化杂志,2014,22(8):1179-1183.DOI: 10.11569/wcjd.v22.i8.1179.
[21] 彭慧芸,袁瑜,谢文瑞,等.早期经鼻肠内营养对中-重度急性胰腺炎患者的疗效观察[J].广州医药,2020,51(2):77-80,98.DOI:10.3969/j.issn.1000-8535.2020.02.017.
|